Ambit Biosciences Corporation AMBI was a big mover last session, as the company saw its shares rise just over 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company, as the stock is now trading above the past one month's volatile price range of $5.94 to $6.96.
This biopharmaceutical company has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate has also remained unchanged over the same time frame. Friday's rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Ambit Biosciences currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Some better-ranked Biomedical stocks worth considering are Gilead Sciences Inc. GILD, Myriad Genetics Inc. MYGN and Illumina Inc. ILMN. All three stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
This biopharmaceutical company has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate has also remained unchanged over the same time frame. Friday's rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Ambit Biosciences currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Some better-ranked Biomedical stocks worth considering are Gilead Sciences Inc. GILD, Myriad Genetics Inc. MYGN and Illumina Inc. ILMN. All three stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMBIT BIOSCIENC AMBI: Free Stock Analysis Report
GILEAD SCIENCES GILD: Free Stock Analysis Report
ILLUMINA INC ILMN: Free Stock Analysis Report
MYRIAD GENETICS MYGN: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
